By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Peregrine Pharmaceuticals, Inc. 

14272 Franklin Avenue, Suite 100

Tustin  California  92780  U.S.A.
Phone: 714-508-6000 Fax: 714-838-5817



AVANIR Pharmaceuticals 

Company News
Peregrine Pharmaceuticals, Inc. (PPHM)' Immuno-Oncology Agent Bavituximab To Be Highlighted In Three Presentations At 2015 ASCO Annual Meeting 5/14/2015 10:44:11 AM
Preclinical Data Presented At AACR Demonstrate Synergistic Anti-Tumor Effects Of Peregrine Pharmaceuticals, Inc. (PPHM)'s Phosphatidylserine (PS)-Targeting Antibodies With Immune Checkpoint Inhibitors In Models Of Melanoma And Breast Cancer 4/21/2015 8:04:09 AM
Data Presented At AACR Demonstrate Peregrine Pharmaceuticals, Inc. (PPHM)' Bavituximab Induces Immune Activation In PD-L1 Negative NSCLC Tumors 4/20/2015 8:28:55 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Three Abstracts Accepted For Presentation At American Association for Cancer Research 2015 Annual Meeting 4/15/2015 4:02:59 PM
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Promising Bavituximab Phase I Data Published In The Peer-Reviewed Journal Cancer Medicine In Advanced Metastatic Breast Cancer 3/31/2015 11:02:49 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Reports Third Quarter Fiscal Year 2015 Financial Results And Recent Developments 3/13/2015 7:18:53 AM
Peregrine Pharmaceuticals, Inc. (PPHM) Declares Quarterly Dividend On Its Series E Convertible Preferred Stock 3/11/2015 7:31:52 AM
Peregrine Pharmaceuticals, Inc. (PPHM) To Report Third Quarter Fiscal 2015 Financial Results After Market On March 12, 2015 3/6/2015 7:33:48 AM
Peregrine Pharmaceuticals, Inc. (PPHM) To Present At The 27th Annual ROTH Conference 3/3/2015 8:23:59 AM
Newly Presented Data Shows That Peregrine Pharmaceuticals, Inc. (PPHM)' PS-Targeting Antibodies Significantly Enhance Anti-Tumor Activity Of Immune Checkpoint Inhibitors PD-1 And CTLA-4 In Models Of Breast Cancer And Melanoma 2/9/2015 12:14:44 PM